Discover
RetinaRounds™
RetinaRounds™
Author: RetinaRounds™
Subscribed: 6Played: 9Subscribe
Share
©RetinaRounds™
Description
Podcast co-hosts Steven Schwartz, MD and Pradeep Prasad, MD interview leaders in the field of vitreroretinal surgery and ophthalmology covering a range of topics including surgical innovation, business in ophthalmology and graduate medical education.
34 Episodes
Reverse
Celebrating 250 episodes with stories of mentorship, wisdom and the people who shaped our careers
Today we’re diving into what it really takes to start your own retina practice. We will discuss the upside of autonomy and ownership, and the very real financial, operational, and lifestyle challenges that come with it. Our guest is Dr. Nadeem Vaidya, who will share his journey and playbook for anyone considering going out on their own.
Today I’m joined by Dr. Daniel Agarwal, a vitreoretinal surgeon at San Luis Obispo Eye Associates on California’s Central Coast. In this episode, Daniel shares hard-earned pearls from his first job search in retina, what he wishes he had focused on, and how those lessons helped him pivot to a second position that was a much better fit both professionally and personally. Whether you’re a fellow sending out your first CVs or an attending rethinking your current role, this is a candid, practical conversation you won’t want to miss.
Today we’re joined by anterior segment expert and guest surgeon of the week, Dr. Steven Safran, who walks us through practical principles for managing complex lens cases that every retina specialist needs to understand.
Retina Rounds is excited to welcome a true leader in ophthalmology and a giant in retina: Dr. Jay Duker. Dr. Duker is one of the most accomplished figures in our field, having served as Chair of Ophthalmology at Tufts Medical Center, where he helped shape both clinical care and research for over two decades. He’s now President and CEO of EyePoint Pharmaceuticals and, in today’s episode, we discuss his remarkable career journey, his transition from academia to biotech, and a fascinating deep dive into tyrosine kinase inhibitors, clinical trial development, and what it really takes to bring a new therapy from concept to regulatory approval.
* Retina Rounds has no financial or conflicts of interest in the content presented








